AcouSort’s participation in Phacilitate last year was highly successful, and the company has seen a growing interest in its solutions from the cell therapy community over the past twelve months. AcouSort currently has several ongoing collaborations and discussions which demonstrates that the technology has a vital role to play in making the manufacturing of cell therapies much more efficient. AcouSort has in advance scheduled meetings with relevant participating companies to make the most of this great opportunity.

“Advanced Therapies Week is the primary networking meeting for industry leaders within cell and gene therapy. It specifically focuses on next generation solutions supporting the biotech industry, thus making the event an excellent opportunity to present the fantastic benefits of our technology,” says Torsten Freltoft, AcouSort’s CEO.

AcouSort will also participate in the CCMA, Canadian Cytometry and Microscopy Association conference in Ottawa on February 6-9, where Agnes Michanek, AcouSort’s Commercial Director, will present the company’s products and the capabilities of AcouSort’s technology. The event is taking place at University of Ottawa, where AcouSort for the past year has been collaborating with Dr Vera Tang on the development of optimized applications for clean-up of dissociate tissue samples before flow cytometry analysis.